Compare KTCC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTCC | NSRX |
|---|---|---|
| Founded | 1969 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.5M | 38.9M |
| IPO Year | 1995 | 2024 |
| Metric | KTCC | NSRX |
|---|---|---|
| Price | $2.76 | $4.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 16.6K | 12.3K |
| Earning Date | 05-05-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $467,871,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.40 | $1.98 |
| 52 Week High | $4.42 | $9.50 |
| Indicator | KTCC | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 24.87 | 64.61 |
| Support Level | $2.57 | $2.90 |
| Resistance Level | $2.89 | $4.49 |
| Average True Range (ATR) | 0.22 | 0.28 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 1.58 | 89.52 |
Key Tronic Corporation provides electronic manufacturing services, including engineering, materials management, manufacturing and assembly, in-house testing, and distribution to various countries. The company serves diverse industries such as pest control, personal protection, air purification, automotive, medical technology, and utilities inspection equipment. Its primary services include integrated electronic and mechanical engineering, precision plastic molding, sheet metal fabrication, printed circuit board (PCB) and complete product assembly. Key Tronic operates manufacturing facilities in the United States, Vietnam, and Mexico, recently expanding with a new facility in Arkansas. Revenue is generated mainly through contract manufacturing and service agreement.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.